Introducing biomarkers for invasive fungal disease in haemato-oncology patients: a single-centre experience.

ABSTRACT: Hypothesis/Gap Statement. The impacts of increased biomarker testing on antifungal prescribing have not yet been fully examined in a real-life setting.Objectives. Biomarkers for invasive fungal disease (IFD) have been shown to reduce antifungal prescriptions in neutropaenic haemato-oncology patients. Our study aimed to assess the real-life impacts of introducing a novel biomarker-based pathway, incorporating serum galactomannan and Aspergillus PCR, for pyrexial haemato-oncology admissions.Methods. Patients with neutropaenic fever were identified prospectively after introduction of the new pathway from 2013-2015. A historical group of neutropaenic patients who had blood cultures taken from 2009-2012 was generated for comparison. Clinical details, including demogr

SUBMITTER: Martinelli AW 

PROVIDER: S-EPMC7613179 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature